# A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

> **NCT06573645** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Xia Yi** · enrollment: 428 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06573645
- **Lead sponsor:** Xia Yi
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2027-01-12
- **Final completion:** 2027-07-12
- **Target enrollment:** 428 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573645, "A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06573645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*